The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
An open study of B lymphocyte depletion in systemic lupus erythematosus
Abstract
Objective: To gain preliminary evidence for the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE). Methods: Six female patients with active SLE, resistant to standard immunosuppressive therapy, were treated on an open‐label basis. During a 2‐week period, each patient received two 500‐mg infusions of rituximab, two 750‐mg infusions of cyclophosphamide, and high‐dose oral corticosteroids. Results: No significant adverse events were observed during followup. Patient 1 had not improved at 3 months but was then lost to followup. At 6 months, all 5 remaining patients had improved, as evidenced by improvement in British Isles Lupus Assessment Group global scores, from a median of 14 (range 9–27) at baseline to a median of 6 (range 3–8) at 6 months. Manifestations of SLE such as fatigue, arthralgia/arthritis, and serositis responded particularly well to this protocol. Hemoglobulin levels increased in patients 2, 3, 5, and 6. The erythrocyte sedimentation rate decreased in patients 2, 3, 4, and 5 and was stable in patient 1. In patients 4 and 5, the urinary protein–to‐creatinine ratio decreased significantly. C3 serum levels increased in all 5 patients who had low levels at baseline; in two of these patients, patients 2 and 5, C3 values were normal at 6 months. The variation in the level of anti–double‐stranded DNA antibody was different in individual patients. Conclusion: This study provides sufficient evidence for the safety and possible efficacy of B lymphocyte depletion therapy in SLE to justify a formal controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
Stasi, R., Pagano, A., Stipa, E., & Amadori, S. (2001) · Blood · doi:10.1182/blood.v98.4.952 · Cited by 549
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J. C. W., & Cambridge, G. (2001) · Rheumatology · doi:10.1093/rheumatology/40.2.205 · Cited by 523
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 345
Self-citationEhrlich, G. E. (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.2.251 · Cited by 261
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
Levine, T. D., & Pestronk, A. (1999) · Neurology · doi:10.1212/wnl.52.8.1701 · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
B cell abnormalities in systemic lupus erythematosus.
Grammer, A. C., & Lipsky, P. E. (2003) · Arthritis Research · doi:10.1186/ar1009 · Cited by 170
Clinical applications of anti-CD20 antibodies
Gopal, A. K., & Press, O. W. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90164-6 · Cited by 97
Cited by
Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Self-citationMerrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409
Self-citationD'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 776
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Manson, J. J., & Rahman, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-6 · Cited by 605
Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1763 · Cited by 584
MAINTENANCE OF SERUM ANTIBODY LEVELS
Manz, R. A., Hauser, A. E., Hiepe, F., & Radbruch, A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115723 · Cited by 539
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Self-citationRituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study
Pijpe, J., van Imhoff, G. W., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G. J., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 500
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
Cambridge, G., Leandro, M. J., Edwards, J. C. W., Ehrenstein, M. R., Salden, M., Bodman‐Smith, M., & Webster, A. D. B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11181 · Cited by 470
Self-citationRituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Gottenberg, J.-E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029694 · Cited by 401
Smith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22046 · Cited by 400
Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial
Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R., & Specks, U. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1144oc · Cited by 399
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 369
Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy
Silverman, G. J., & Weisman, S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10947 · Cited by 367
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
Self-citationPatel, V. L., Mahévas, M., Lee, S. Y., Stasi, R., Cunningham-Rundles, S., Godeau, B., Kanter, J., Neufeld, E., Taube, T., Ramenghi, U., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393975 · Cited by 348
Tokunaga, M., Saito, K., Kawabata, D., Imura, Y., Fujii, T., Nakayamada, S., Tsujimura, S., Nawata, M., Iwata, S., Azuma, T., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057885 · Cited by 343
Aringer, M., Graninger, W. B., Steiner, G., & Smolen, J. S. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20576 · Cited by 342
Cooper, N., Stasi, R., Cunningham‐Rundles, S., Feuerstein, M. A., Leonard, J. P., Amadori, S., & Bussel, J. B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04889.x · Cited by 336
Anolik, J. H., Barnard, J., Owen, T., Zheng, B., Kemshetti, S., Looney, R. J., & Sanz, I. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22810 · Cited by 333
Sato, S., Fujimoto, M., Hasegawa, M., & Takehara, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20274 · Cited by 317
Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)
Devauchelle‐Pensec, V., Pennec, Y., Morvan, J., Pers, J., Daridon, C., Jousse‐Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Roué, I. Q., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22536 · Cited by 315
A review of the current use of rituximab in autoimmune diseases
Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314
Sites and Stages of Autoreactive B Cell Activation and Regulation
Shlomchik, M. J. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.004 · Cited by 312
Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1942 · Cited by 306
Vigna-Perez, M., Hernández-Castro, B., Paredes-Saharopulos, O., Portales-Pérez, D., Baranda, L., Abud-Mendoza, C., & González-Amaro, R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1954 · Cited by 303
Dall'Era, M., Chakravarty, E., Wallace, D., Genovese, M., Weisman, M., Kavanaugh, A., Kalunian, K., Dhar, P., Vincent, E., Pena‐Rossi, C., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23047 · Cited by 294
Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus
Burt, R. K. (2006) · JAMA · doi:10.1001/jama.295.5.527 · Cited by 290
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Lu, T. Y. ‐., Ng, K. P., Cambridge, G., Leandro, M. J., Edwards, J. C. W., Ehrenstein, M., & Isenberg, D. A. (2009) · Arthritis Care & Research · doi:10.1002/art.24341 · Cited by 275
Self-citationAnti-CD20 (rituximab) treatment improves atopic eczema
Simon, D., Hösli, S., Kostylina, G., Yawalkar, N., & Simon, H.-U. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.016 · Cited by 255
Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis
Gomez Mendez, L. M., Cascino, M. D., Garg, J., Katsumoto, T. R., Brakeman, P., Dall’Era, M., Looney, R. J., Rovin, B., Dragone, L., & Brunetta, P. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01070118 · Cited by 188
Metadata
- Authors
- Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 46
- Issue
- 10
- Pages
- 2673-2677
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2017709470
- Cited by
- 576
- References
- 12
- FWCI
- 27.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.